PeptideDB

Ibuprofen piconol

CAS: 64622-45-3 F: C19H23NO2 W: 297.39

Ibuprofen piconol is a non-steroidal, anti-inflammatory (NSAID) agent for the topical relief of primary thermal burns an
Sales Email:peptidedb@qq.com

This product is for research use only, not for human use. We do not sell to patients.

Bioactivity Ibuprofen piconol is a non-steroidal, anti-inflammatory (NSAID) agent for the topical relief of primary thermal burns and sunburns.
Invitro Ibuprofen piconol is a chemically stable, slightly hygroscopic liquid that strongly partitions into the oil phase and shows no indication of surface activity. This drug has very limited solubility in water (16.5 ppm), modest solubility in glycerol (16.4 mg/mL), and is miscible with less polar organics except for silicone fluids[1]. Varying the initial concentration of ibuprofen piconol does not alter the hydrolysis half-life (concentration range from 50 to 200 μg/mL). The anticoagulant used alters the hydrolysis half-life. For plasma, the half-life is shortest when no anticoagulant is present (t1/2=2.5 h) and longer with the presence of anticoagulants; t1/2=8.0 h for citrate, t1/2=15.5 h for heparin and t1/2=161.8 h for EDTA. Red blood cell uptake of ibuprofen piconol is minimal and ranges from 0.4 to 4.1% over the ibuprofen piconol concentrations used in the study[2].
In Vivo When ibuprofen piconol is applied topically, only ibuprofen and its metabolites are observed in plasma and urine. The conversion of ibuprofen piconol to ibuprofen appears to be extremely rapid in vivo[2].
Name Ibuprofen piconol
CAS 64622-45-3
Formula C19H23NO2
Molar Mass 297.39
Appearance Liquid
Transport Room temperature in continental US; may vary elsewhere.
Storage
Pure form -20°C 3 years
4°C 2 years
In solvent -80°C 6 months
-20°C 1 month
Reference [1]. Pesheck CV, et al. Preformulation characterization of topical Ibuprofen Piconol. Drug Development and Industrial Pharmacy Vol. 19 , Iss. 15,1993 [2]. Christensen JM, et al. Ibuprofen piconol hydrolysis in vitro in plasma, whole blood, and serum using different anticoagulants. J Pharm Sci. 1991 Jan;80(1):29-31.